Pulmonary fibrosis is a condition that causes lung scarring and stiffness. It develops when the alveoli, tiny air sacs that transfer oxygen to the blood, become damaged and inflamed. Body tries to heal the damage with scars, but these scars collapse the alveoli and make the lungs less elastic. Changes in the lungs can also increase the blood pressure in the pulmonary artery. This condition, called pulmonary hypertension, makes the heart work harder and it may fail.
Statistical analysis of pulmonary fibrosis in Poland resulted as the Fourteen studies were included in the review of clinical effectiveness, of which one evaluated azathioprine, three N-acetylcysteine [NAC] (alone or in combination), four pirfenidone, one nintedanib, one sildenafil, one thalidomide, two pulmonary rehabilitation, and one a disease management programme.